April 25, 2023 – Emerging from stealth mode, Radiant’s financing enables the Company to continue rapidly advancing its Multabodies that have application across multiple diseases including cancer.
Read More from FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies
March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.
Read More from CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer